Biopharma companies—including AstraZeneca, BioNTech and Agios—peered farther into the future on the second day of JPM, setting both revenue and R&D targets through the end of the decade.Read More
JPM26 Day 2: Companies Lay Out Near-Term Revenue, Longer-Term Business Goals
